Corpus ID: 21506377

[Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].

@article{Trapeznikova2009CurrentTI,
  title={[Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].},
  author={M. Trapeznikova and K. Pozdniakov and G. Golubev and S. Terpigorev and M. V. Agel'tsov and V. Kuznetsov and M. Shvedov},
  journal={Urologiia},
  year={2009},
  volume={1},
  pages={
          35-40
        }
}
  • M. Trapeznikova, K. Pozdniakov, +4 authors M. Shvedov
  • Published 2009
  • Medicine
  • Urologiia
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU). Seventy PA patients were divided into two groups. Group 1 (n = 35) patients had no ARU. They received kamiren XL in a dose 4 mg/day for 1 month. Group 2 (n = 35) patients received the same doses of kamiren XL in addition to urethral catheterization for 3-7 days. In group 1 efficacy of the… CONTINUE READING

    Topics from this paper